Mirski S E, Cole S P
Department of Oncology, Queen's University, Kingston, Ontario, Canada.
Cancer Res. 1989 Oct 15;49(20):5719-24.
In a previous study (S.E.L. Mirski et al., Cancer Res., 47: 2594-2598, 1987), we described the derivation of a multidrug-resistant small cell lung cancer cell line, H69AR. The H69AR cell line does not over-express P-glycoprotein and is therefore a useful model for the investigation of alternate mechanisms of drug resistance. In this paper we report the production and preliminary characterization of six murine monoclonal antibodies (MAbs) which react selectively with the H69AR cell line compared to its drug-sensitive parent cell line, NCI-H69. One of these antibodies, MAb 2.54, detects a cell surface epitope and reacts with multiple proteins of molecular weight 24,500-34,500 on immunoblots. Non-cell surface membrane-associated epitopes are detected by the other five antibodies, MAbs 3.50, 3.80, 3.177, 3.187, and 3.186. MAbs 3.50 and 3.186 immunoprecipitate antigens of molecular weight 55,000 and 36,000, respectively, while MAbs 3.80, 3.177, and 3.187 all precipitate a molecular weight 47,000 protein, suggesting that they may detect epitopes on the same antigen. The epitopes detected by all six antibodies are present on greater than 80% of H69AR cells, as determined by flow cytometry. With the exception of MAb 2.54, the MAbs cross-react in an enzyme-linked immunosorbent assay with the multidrug-resistant human fibrosarcoma cell line HT1080/DR4. Thus, these MAbs react with two drug-resistant cell lines derived from different tumor types in which overexpression of P-glycoprotein is undetectable. These MAbs may detect novel markers for drug resistance and thus may have potential diagnostic or therapeutic value.
在之前的一项研究中(S.E.L. 米尔斯基等人,《癌症研究》,47: 2594 - 2598, 1987),我们描述了一种多药耐药性小细胞肺癌细胞系H69AR的衍生过程。H69AR细胞系不会过度表达P - 糖蛋白,因此是研究耐药性替代机制的有用模型。在本文中,我们报告了六种鼠单克隆抗体(MAb)的产生及其初步特性,这些抗体与药物敏感的亲本细胞系NCI - H69相比,能选择性地与H69AR细胞系发生反应。其中一种抗体MAb 2.54能检测到细胞表面表位,并且在免疫印迹中与分子量为24,500 - 34,500的多种蛋白质发生反应。另外五种抗体MAb 3.50、3.80、3.177、3.187和3.186能检测到非细胞表面膜相关表位。MAb 3.50和3.186分别免疫沉淀分子量为55,000和36,000的抗原,而MAb 3.80、3.177和3.187都沉淀出一种分子量为47,000的蛋白质,这表明它们可能检测到同一抗原上的表位。通过流式细胞术测定,所有六种抗体检测到的表位在超过80%的H69AR细胞上存在。除MAb 2.54外,这些单克隆抗体在酶联免疫吸附测定中与多药耐药性人纤维肉瘤细胞系HT1080/DR4发生交叉反应。因此,这些单克隆抗体与两种源自不同肿瘤类型且未检测到P - 糖蛋白过度表达的耐药细胞系发生反应。这些单克隆抗体可能检测到耐药性的新标志物,因此可能具有潜在的诊断或治疗价值。